Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study

被引：0
|
作者：
Jun Guo
Yiran Huang
Xu Zhang
Fangjian Zhou
Yinghao Sun
Shukui Qin
Zhangqun Ye
Hui Wang
Annette Jappe
Patrick Straub
Nicoletta Pirotta
Sven Gogov
机构：
[1] Peking University Cancer Hospital and Institute,
[2] Shanghai Renji Hospital,undefined
[3] The General Hospital of PLA,undefined
[4] Sun Yat-sen University Cancer Center,undefined
[5] Shanghai Changhai Hospital,undefined
[6] Nanjing Bayi Hospital,undefined
[7] Wuhan Tongji Hospital,undefined
[8] Beijing Novartis Pharma Company,undefined
[9] Ltd.,undefined
[10] Novartis Pharma AG,undefined
[11] Novartis Pharma AG,undefined
[12] Novartis Pharma AG,undefined
[13] Novartis Pharma AG,undefined
来源：
BMC Cancer | / 13卷
关键词：
Asian; Everolimus; mTOR inhibitor; Renal cell cancer; Sunitinib; Sorafenib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study
    Guo, Jun
    Huang, Yiran
    Zhang, Xu
    Zhou, Fangjian
    Sun, Yinghao
    Qin, Shukui
    Ye, Zhangqun
    Wang, Hui
    Jappe, Annette
    Straub, Patrick
    Pirotta, Nicoletta
    Gogov, Sven
    BMC CANCER, 2013, 13
  • [2] Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor
    Park, Kwonoh
    Lee, Jae-Lyun
    Ahn, Jin-Hee
    Lee, Kyoo Hyung
    Jeong, In-Gab
    Song, Cheryn
    Hong, Bumsik
    Hong, Jun Hyuk
    Ahn, Hanjong
    CANCER RESEARCH AND TREATMENT, 2014, 46 (04): : 339 - 347
  • [3] Safety and efficacy of everolimus in Asian patients with metastatic renal cell carcinoma (mRCC) who failed previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: A subanalysis of REACT
    Rha, Sun Young
    Lee, Se-Hoon
    Ou, Yen-Chuan
    Ahn, Jin-Hee
    Chang, Yen-Hwa
    Srimuninnimit, Vichien
    Lim, Ho Yeong
    Chung, Ik-Joo
    Pang, See-Tong
    Xue, Hong-Ling
    Panneerselvam, Ashok
    Chung, Jooseop
    Toh, Chee-Keong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
    Gruenwald, Viktor
    Karakiewicz, Pierre I.
    Bavbek, Sevil E.
    Miller, Kurt
    Machiels, Jean-Pascal
    Lee, Se-Hoon
    Larkin, James
    Bono, Petri
    Rha, Sun Young
    Castellano, Daniel
    Blank, Christian U.
    Knox, Jennifer J.
    Hawkins, Robert
    Anak, Oezlem
    Rosamilia, Marianne
    Booth, Jocelyn
    Pirotta, Nicoletta
    Bodrogi, Istvan
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (03) : 324 - 332
  • [5] Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies
    Wiele, Andrew J.
    Bathala, Tharakeswara K.
    Hahn, Andrew W.
    Xiao, Lianchun
    Duran, Munevver
    Ross, Jeremy A.
    Jonasch, Eric
    Shah, Amishi Y.
    Campbell, Matthew T.
    Msaouel, Pavlos
    Tannir, Nizar M.
    ONCOLOGIST, 2021, 26 (06): : 476 - 482
  • [6] Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study
    Calvo, E.
    Escudier, B.
    Motzer, R. J.
    Oudard, S.
    Hutson, T. E.
    Porta, C.
    Bracarda, S.
    Gruenwald, V.
    Thompson, J. A.
    Ravaud, A.
    Kim, D.
    Panneerselvam, A.
    Anak, O.
    Figlin, R. A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (03) : 333 - 339
  • [7] Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial
    Ma, Jianhui
    Song, Yan
    Shou, Jianzhong
    Bai, Yuxian
    Li, Hanzhong
    Xie, Xiaodong
    Luo, Hong
    Ren, Xiubao
    Liu, Jiyan
    Ye, Dingwei
    Bai, Xianzhong
    Fu, Cheng
    Qin, Shukui
    Wang, Jinwan
    Zhou, Ai-Ping
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [8] Subgroup analysis of the phase 3 RECORD-1 trial of everolimus in patients with metastatic renal cell carcinoma: 1 versus 2 prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies
    Figlin, R. A.
    Motzer, R.
    Hutson, T. E.
    Oudard, S.
    Porta, C.
    Gruenwald, V.
    Ravaud, A.
    Panneerselvam, A.
    Calvo, E.
    BJU INTERNATIONAL, 2012, 109 : 4 - 5
  • [9] Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Park, Seongjoon
    Ahn, Yongcheol
    Ahn, Jin-Hee
    Kim, Tae-Won
    Ahn, Shin
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (04) : 687 - 693
  • [10] Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features
    Jae-Lyun Lee
    Inkeun Park
    Kwonoh Park
    Seongjoon Park
    Yongcheol Ahn
    Jin-Hee Ahn
    Tae-Won Kim
    Shin Ahn
    Cheryn Song
    Jun Hyuk Hong
    Choung-Soo Kim
    Hanjong Ahn
    Journal of Cancer Research and Clinical Oncology, 2012, 138 : 687 - 693
12345